Alzheimer’s disease: endolysosome and autophagy modulation

• Mutations causal for monogenic Alzheimer’s disease (PSEN1, APP) disrupt the endolysosome and authophagy systems in human neurons
• Talisman has developed a human stem cell platform for validating targets that rescue lysosome and autophagy function in models of monogenic AD
• Used to test multiple therapeutic modalities: small molecules, genome engineering and ASOs
• Talisman is using this platform for in-house whole-genome screens to identify novel druggable targets and pathways